A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors
暂无分享,去创建一个
Anyue Yin | Dirk Jan A R Moes | Johan G C van Hasselt | Jesse J Swen | Henk-Jan Guchelaar | H. Guchelaar | J. Swen | D. Moes | J. V. van Hasselt | A. Yin | J. G. V. van Hasselt
[1] Yongzhao Shao,et al. Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates , 2016, Scientific Reports.
[2] James D. Brenton,et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.
[3] Kazuyuki Aihara,et al. Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer. , 2010, Journal of theoretical biology.
[4] J. Murray,et al. Glioblastoma brain tumours: estimating the time from brain tumour initiation and resolution of a patient survival anomaly after similar treatment protocols , 2012, Journal of biological dynamics.
[5] F. Ghalichi,et al. Image based modeling of tumor growth , 2016, Australasian Physical & Engineering Sciences in Medicine.
[6] Thomas E Yankeelov,et al. Clinically Relevant Modeling of Tumor Growth and Treatment Response , 2013, Science Translational Medicine.
[7] J G Coen van Hasselt,et al. Towards integrative systems pharmacology models in oncology drug development. , 2015, Drug discovery today. Technologies.
[8] K. Swanson,et al. A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof of principle , 2007, British Journal of Cancer.
[9] D. Levy,et al. An elementary approach to modeling drug resistance in cancer. , 2010, Mathematical biosciences and engineering : MBE.
[10] R Bruno,et al. Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First‐Line Gastric Cancer and Elevated Plasma VEGF‐A , 2016, CPT: pharmacometrics & systems pharmacology.
[11] Hervé Delingette,et al. Personalized Radiotherapy Planning Based on a Computational Tumor Growth Model , 2017, IEEE Transactions on Medical Imaging.
[12] B. Ribba,et al. Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2 , 2016, Cancer Chemotherapy and Pharmacology.
[13] Gargi Chakraborty,et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. , 2009, Cancer research.
[14] Lena E Friberg,et al. Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response , 2013, British journal of clinical pharmacology.
[15] I. Trocóniz,et al. Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications. , 2016, The oncologist.
[16] Valder Steffen,et al. Determination of an optimal control strategy for drug administration in tumor treatment using multi-objective optimization differential evolution , 2016, Comput. Methods Programs Biomed..
[17] Ezio Venturino,et al. A two-clones tumor model: Spontaneous growth and response to treatment. , 2016, Mathematical biosciences.
[18] Trevor A Graham,et al. New paradigms in clonal evolution: punctuated equilibrium in cancer , 2016, The Journal of pathology.
[19] L E Friberg,et al. A Review of Mixed-Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis , 2014, CPT: pharmacometrics & systems pharmacology.
[20] Yuri Kogan,et al. Predicting Outcomes of Prostate Cancer Immunotherapy by Personalized Mathematical Models , 2010, PloS one.
[21] Johan Hartman,et al. Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing , 2018, Cell.
[22] Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation , 2016, BMC Cancer.
[23] Fang-Fang Hao,et al. A nonlinear competitive model of the prostate tumor growth under intermittent androgen suppression. , 2016, Journal of theoretical biology.
[24] Anubha Gupta,et al. Population pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes , 2014, Journal of clinical pharmacology.
[25] R. F. Allen. A Commentary , 1966 .
[26] Johannes G. Reiter,et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.
[27] Nicolas André,et al. Computational oncology — mathematical modelling of drug regimens for precision medicine , 2016, Nature Reviews Clinical Oncology.
[28] D. Wodarz,et al. Mathematical Modeling of Cyclic Cancer Treatments , 2014 .
[29] K. Badani,et al. Heterogeneity in renal cell carcinoma. , 2017, Urologic oncology.
[30] Pietro Cerveri,et al. Adaptive Mathematical Model of Tumor Response to Radiotherapy Based on CBCT Data , 2016, IEEE Journal of Biomedical and Health Informatics.
[31] Thomas E Yankeelov,et al. Integration of diffusion‐weighted MRI data and a simple mathematical model to predict breast tumor cellularity during neoadjuvant chemotherapy , 2011, Magnetic resonance in medicine.
[32] A. Murugan,et al. Chemotherapy for tumors: an analysis of the dynamics and a study of quadratic and linear optimal controls. , 2007, Mathematical biosciences.
[33] Vishal Patel,et al. Image-driven modeling of the proliferation and necrosis of glioblastoma multiforme , 2017, Theoretical Biology and Medical Modelling.
[34] Zvia Agur,et al. Personalizing oncology treatments by predicting drug efficacy, side‐effects, and improved therapy: mathematics, statistics, and their integration , 2014, Wiley interdisciplinary reviews. Systems biology and medicine.
[35] Gouhei Tanaka,et al. A Mathematical Model of Intermittent Androgen Suppression for Prostate Cancer , 2008, J. Nonlinear Sci..
[36] Huimin Wang,et al. Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients , 2017, Oncotarget.
[37] Martin A Nowak,et al. Dynamics of targeted cancer therapy. , 2012, Trends in molecular medicine.
[38] Dominik Wodarz,et al. Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL) , 2014, Proceedings of the National Academy of Sciences.
[39] Camille Stephan-Otto Attolini,et al. Evolutionary Theory of Cancer , 2009, Annals of the New York Academy of Sciences.
[40] Thomas E Yankeelov,et al. A mechanically coupled reaction–diffusion model for predicting the response of breast tumors to neoadjuvant chemotherapy , 2013, Physics in medicine and biology.
[41] J. Gerring. A case study , 2011, Technology and Society.
[42] Leslie Roberts,et al. A Proof of Principle , 2007, Science.
[43] M. Gottesman,et al. The Impact of Cell Density and Mutations in a Model of Multidrug Resistance in Solid Tumors , 2014, Bulletin of Mathematical Biology.
[44] T. Fojo,et al. Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. , 2008, The oncologist.
[45] P Forouhi,et al. Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response , 2000, British Journal of Cancer.
[46] T. Fojo,et al. Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. , 2008, The oncologist.
[47] Franziska Michor,et al. Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution. , 2017, Cancer research.
[48] M. Gottesman,et al. The Role of Cell Density and Intratumoral Heterogeneity in Multidrug Resistance , 2013 .
[49] Bin Hu,et al. Mathematical modeling and computational prediction of cancer drug resistance , 2017, Briefings Bioinform..
[50] Fei Li,et al. Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients , 2015, PloS one.
[51] Nenad Sarapa,et al. Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] D. Lauffenburger,et al. Modeling Tumor Clonal Evolution for Drug Combinations Design. , 2016, Trends in cancer.
[53] T. Fojo,et al. Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy , 2010, Clinical Cancer Research.
[54] D. Juric,et al. Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies. , 2014, British journal of clinical pharmacology.
[55] Udo Schumacher,et al. Simulation of metastatic progression using a computer model including chemotherapy and radiation therapy , 2015, J. Biomed. Informatics.
[56] Vangelis Sakkalis,et al. Evaluation framework for the multilevel macroscopic models of solid tumor growth in the glioma case , 2010, 2010 Annual International Conference of the IEEE Engineering in Medicine and Biology.
[57] Martin A Nowak,et al. Evolution of Resistance During Clonal Expansion , 2006, Genetics.
[58] Luc Taillandier,et al. Computational modeling of the WHO grade II glioma dynamics: principles and applications to management paradigm , 2008, Neurosurgical Review.
[59] Chen-Hsiang Yeang,et al. Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer , 2012, Proceedings of the National Academy of Sciences.
[60] R. Bruno,et al. Exploratory Modeling and Simulation to Support Development of Motesanib in Asian Patients With Non–Small Cell Lung Cancer Based on MONET1 Study Results , 2014, Clinical pharmacology and therapeutics.
[61] N. Enas,et al. Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer. , 2016, British journal of clinical pharmacology.
[62] K Hendrickson,et al. Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach , 2010, Physics in medicine and biology.
[63] N. Dubin. Mathematical Model , 2022 .
[64] Jan Fagerberg,et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] J. Panetta,et al. Using Pharmacokinetic and Pharmacodynamic Modeling and Simulation to Evaluate Importance of Schedule in Topotecan Therapy for Pediatric Neuroblastoma , 2008, Clinical Cancer Research.
[66] Dominik Wodarz,et al. Drug resistance in cancer: principles of emergence and prevention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[67] Ami Radunskaya,et al. The dynamics of an optimally controlled tumor model: A case study , 2003 .
[68] Albert Lai,et al. Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. , 2009, Cancer research.
[69] David Basanta,et al. Exploiting evolution to treat drug resistance: combination therapy and the double bind. , 2011, Molecular pharmaceutics.
[70] B P Booth,et al. Elucidation of Relationship Between Tumor Size and Survival in Non‐Small‐Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development , 2009, Clinical pharmacology and therapeutics.
[71] F. Michor,et al. Evolution of acquired resistance to anti-cancer therapy. , 2014, Journal of theoretical biology.
[72] N. Komarova,et al. Stochastic modeling of drug resistance in cancer. , 2006, Journal of theoretical biology.
[73] Franziska Michor,et al. Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies , 2009, PLoS Comput. Biol..
[74] Kazuyuki Aihara,et al. Model predictive control for optimally scheduling intermittent androgen suppression of prostate cancer. , 2014, Methods.
[75] A. Samson,et al. Analysis of temozolomide resistance in low‐grade gliomas using a mechanistic mathematical model , 2017, Fundamental & clinical pharmacology.
[76] Gouhei Tanaka,et al. Mathematical modelling of prostate cancer growth and its application to hormone therapy , 2010, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.
[77] E. Holmgren,et al. Endpoints for agents that slow tumor growth. , 2007, Contemporary clinical trials.
[78] U. Ledzewicz,et al. On drug resistance and metronomic chemotherapy: A mathematical modeling and optimal control approach. , 2016, Mathematical biosciences and engineering : MBE.
[79] Urszula Ledzewicz,et al. Realizable protocols for optimal administration of drugs in mathematical models for anti-angiogenic treatment. , 2010, Mathematical medicine and biology : a journal of the IMA.
[80] W. Pope,et al. Modeling the efficacy of the extent of surgical resection in the setting of radiation therapy for glioblastoma , 2016, Cancer science.
[81] Joseph D Butner,et al. Simulating cancer growth with multiscale agent-based modeling. , 2015, Seminars in cancer biology.
[82] Martin A Nowak,et al. Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers , 2014, Proceedings of the National Academy of Sciences.
[83] Peter L. Bonate,et al. Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma , 2013, Cancer Chemotherapy and Pharmacology.
[84] Thomas E Yankeelov,et al. Predicting the Response of Breast Cancer to Neoadjuvant Therapy Using a Mechanically Coupled Reaction-Diffusion Model. , 2015, Cancer research.
[85] F. Markowetz,et al. Cancer Evolution: Mathematical Models and Computational Inference , 2014, Systematic biology.
[86] S. Halachmi,et al. Improving Bacillus Calmette-Guérin (BCG) immunotherapy for bladder cancer by adding interleukin 2 (IL-2): a mathematical model. , 2016, Mathematical medicine and biology : a journal of the IMA.
[87] B. Houk,et al. Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients , 2015, Cancer Chemotherapy and Pharmacology.
[88] Kristin R. Swanson,et al. The Evolution of Mathematical Modeling of Glioma Proliferation and Invasion , 2007, Journal of neuropathology and experimental neurology.
[89] Paolo Magni,et al. Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents , 2004, Cancer Research.
[90] Ali Najafi,et al. Seminars in Cancer Biology , 2014 .
[91] M. Karlsson,et al. PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST , 2013, CPT: pharmacometrics & systems pharmacology.
[92] D. Ouellet,et al. Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma , 2015, CPT: pharmacometrics & systems pharmacology.
[93] José Pinheiro,et al. Model‐based clinical drug development in the past, present and future: a commentary , 2015, British journal of clinical pharmacology.
[94] Carl T. Bergstrom,et al. Dynamics of preventive vs post-diagnostic cancer control using low-impact measures , 2015, eLife.
[95] Jean Clairambault,et al. Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation. , 2016, Biochimica et biophysica acta.
[96] Yang Kuang,et al. Mechanisms of resistance to intermittent androgen deprivation in patients with prostate cancer identified by a novel computational method. , 2014, Cancer research.
[97] F. Michor,et al. Evolution of resistance to anti-cancer therapy during general dosing schedules. , 2010, Journal of theoretical biology.
[98] Johan Pallud,et al. A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy , 2012, Clinical Cancer Research.
[99] D. Wodarz,et al. Effect of cellular quiescence on the success of targeted CML therapy , 2022 .
[100] Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial , 2012, BMC Cancer.
[101] Shea N Gardner,et al. Modeling multi-drug chemotherapy: tailoring treatment to individuals. , 2002, Journal of theoretical biology.
[102] Antoine Ferreira,et al. Modeling of Optimal Targeted Therapies Using Drug-Loaded Magnetic Nanoparticles for Liver Cancer , 2016, IEEE Transactions on NanoBioscience.
[103] Natalia L Komarova,et al. The Worst Drug Rule Revisited: Mathematical Modeling of Cyclic Cancer Treatments , 2011, Bulletin of mathematical biology.
[104] M. Maitland,et al. Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling , 2016, Clinical and translational science.